News Venus Medtech (Hangzhou) Inc.

Equities

2500

CNE100003PJ8

Market Closed - Hong Kong S.E. Other stock markets 03:08:30 2023-11-22 am EST			5-day change	1st Jan Change
5.62 ^HKD	-0.71%		-.--%	-.--%

Apr. 01	Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21%	MT
Mar. 28	Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21%	Mar. 31	MT
Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Venus Medtech Inc.(SEHK:2500) dropped from S&P Global BMI Index	Mar. 17	CI
Venus Medtech Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away	Feb. 07	CI
Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval	Feb. 05	AQ
Venus Medtech Names Former 3SBio Finance Chief as CFO	Jan. 04	MT
Venus Medtech Inc. Appoints Fei Wang as the Chief Financial Officer	Jan. 04	CI
Venus Medtech Gets Trading Resumption Guidance	Dec. 27	MT
Venus Medtech Inc. Approves Mr. Liqiao Ma as an Executive Director	Dec. 15	CI
Venus Medtech Concludes Probe into Funds Loaned to Ex-Directors; Declares Remedial Action	Nov. 28	MT
Venus Medtech to Market Valgen Medtech's Heart Valve Repair System Across China	Nov. 22	MT
Venus Medtech Inc. Announces Executive Changes	Nov. 20	CI
Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023	Nov. 18	AQ
Venus Medtech Names Joint CEO	23-09-24	MT
Venus Medtech Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023	23-09-22	CI
Venus Medtech's H1 Attributable Loss Widens	23-08-31	MT
Venus Medtech Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
US FDA Grants Clinical Trial Approval to Venus Medtech's Pulmonary Valve Replacement	23-08-06	MT
Venus Medtech Inc. Announces it's Self-Developed Transcatheter Pulmonary Valve Replacement System VenusP-Valve Received the Approval of IDE (Investigational Device Exemption) Application from the US Food and Drug Administration	23-08-06	CI
Venus Medtech’s General Manager Boosts Shareholding to 12%	23-06-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Venus Medtech (Hangzhou) Inc.

Equities

2500

CNE100003PJ8

Summary

Filters